Search:
![](/images/loading2.gif)
You do not have permission to access this chart.
Please Sign Up or Login
News for Cassava Sciences, Inc. (SAVA)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a day ago | The Motley Fool
2 days ago | InvestorPlace
2 days ago | The Motley Fool
3 days ago | PRNewsWire
4 days ago | The Motley Fool
4 days ago | InvestorPlace
5 days ago | The Motley Fool
6 days ago | InvestorPlace
a week ago | InvestorPlace
a week ago | The Motley Fool
About:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.